AXQ Capital LP Acquires Shares of 10,761 Arcus Biosciences, Inc. (NYSE:RCUS)

AXQ Capital LP bought a new position in Arcus Biosciences, Inc. (NYSE:RCUS) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 10,761 shares of the company’s stock, valued at approximately $160,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. R Squared Ltd bought a new stake in Arcus Biosciences in the 4th quarter worth about $26,000. Point72 Hong Kong Ltd bought a new position in shares of Arcus Biosciences in the third quarter valued at approximately $47,000. US Bancorp DE increased its position in shares of Arcus Biosciences by 2,432.0% during the fourth quarter. US Bancorp DE now owns 6,887 shares of the company’s stock valued at $103,000 after acquiring an additional 6,615 shares during the last quarter. Quest Partners LLC lifted its holdings in Arcus Biosciences by 40,904.3% during the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after acquiring an additional 9,408 shares during the period. Finally, Teacher Retirement System of Texas boosted its position in Arcus Biosciences by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock worth $223,000 after purchasing an additional 2,410 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, Director Yasunori Kaneko purchased 20,000 shares of the stock in a transaction on Thursday, February 27th. The stock was acquired at an average cost of $10.06 per share, with a total value of $201,200.00. Following the completion of the purchase, the director now directly owns 28,400 shares of the company’s stock, valued at approximately $285,704. This trade represents a 238.10 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Robert C. Goeltz II sold 3,594 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the sale, the chief financial officer now owns 60,138 shares of the company’s stock, valued at $902,070. This represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 12.30% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Bank of America lowered their target price on Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. HC Wainwright raised shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $18.00 to $24.00 in a research report on Wednesday, February 26th. Finally, Morgan Stanley reduced their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $30.25.

Arcus Biosciences Stock Up 2.3 %

RCUS opened at $9.15 on Tuesday. The company has a 50 day moving average of $11.57 and a 200 day moving average of $14.55. The company has a market cap of $961.49 million, a PE ratio of -2.90 and a beta of 1.36. Arcus Biosciences, Inc. has a 12 month low of $8.82 and a 12 month high of $19.11. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million. On average, sell-side analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.